NASDAQ:ORPH

Orphazyme A/S News Headlines

$9.33
-11.67 (-55.57 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.05
$16.01
50-Day Range
$4.82
$21.00
52-Week Range
$4.75
$77.77
Volume42.18 million shs
Average Volume491,081 shs
Market Capitalization$326.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Orphazyme A/S (NASDAQ ORPH) News Headlines Today

SourceHeadline
Reddit’s Stock Gamblers Are Landing on a Few European BetsReddit’s Stock Gamblers Are Landing on a Few European Bets
bloomberg.com - June 11 at 12:17 PM
Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeOrphazyme stock losing half its value premarket, after rocketing fourfold the day before
msn.com - June 11 at 12:17 PM
The New Meme Stock Is a Danish Biotech Firm That Spiked 1,387%The New Meme Stock Is a Danish Biotech Firm That Spiked 1,387%
ca.finance.yahoo.com - June 11 at 12:17 PM
Orphazyme A/S (NASDAQ:ORPH) Shares Gap Down to $21.00Orphazyme A/S (NASDAQ:ORPH) Shares Gap Down to $21.00
americanbankingnews.com - June 11 at 10:26 AM
Danes Get a New Meme Stock After 1,387% Spike in U.S. HoursDanes Get a New Meme Stock After 1,387% Spike in U.S. Hours
bloomberg.com - June 11 at 7:17 AM
Did You Ride The Rally In Orphazyme?Did You Ride The Rally In Orphazyme?
nasdaq.com - June 11 at 7:17 AM
Orphazyme addresses recent trading activityOrphazyme addresses recent trading activity
finance.yahoo.com - June 11 at 7:17 AM
The New Meme Stock Is a Danish Biotech Firm That Spiked 1,387%The New Meme Stock Is a Danish Biotech Firm That Spiked 1,387%
finance.yahoo.com - June 11 at 7:17 AM
Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?
benzinga.com - June 10 at 10:59 PM
Orphazyme A/S (NASDAQ:ORPH) Hits New 12-Month High at $77.77Orphazyme A/S (NASDAQ:ORPH) Hits New 12-Month High at $77.77
americanbankingnews.com - June 10 at 7:24 PM
Orphazyme A/S (NASDAQ:ORPH) Short Interest Up 28.1% in MayOrphazyme A/S (NASDAQ:ORPH) Short Interest Up 28.1% in May
americanbankingnews.com - June 1 at 2:18 AM
Reviewing Orphazyme A/S (ORPH) & The CompetitionReviewing Orphazyme A/S (ORPH) & The Competition
americanbankingnews.com - May 30 at 11:26 AM
Orphazyme A/S (ORPH) versus Its Competitors Head-To-Head ReviewOrphazyme A/S (ORPH) versus Its Competitors Head-To-Head Review
americanbankingnews.com - May 30 at 11:26 AM
Orphazyme A/S (NASDAQ:ORPH)  Shares Down 3.3% Orphazyme A/S (NASDAQ:ORPH) Shares Down 3.3%
americanbankingnews.com - May 21 at 12:56 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S  - ORPHSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH
finance.yahoo.com - May 18 at 9:29 AM
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Orphazyme A/S (ORPH) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Investors of Orphazyme A/S (ORPH) Investigation
finance.yahoo.com - May 11 at 5:58 PM
Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares SlideMid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide
markets.businessinsider.com - May 7 at 2:44 PM
Orphazyme Shares Plummet As Arimoclomol Flunks In Amyotrophic Lateral Sclerosis StudyOrphazyme Shares Plummet As Arimoclomol Flunks In Amyotrophic Lateral Sclerosis Study
finance.yahoo.com - May 7 at 2:44 PM
Cronos Q1 Earnings Impacted By COVID-19 Related RestrictionsCronos Q1 Earnings Impacted By COVID-19 Related Restrictions
finance.yahoo.com - May 7 at 2:44 PM
Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
markets.businessinsider.com - May 7 at 4:38 AM
Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - May 7 at 4:38 AM
Orphazyme to present at upcoming investor conferencesOrphazyme to present at upcoming investor conferences
finance.yahoo.com - April 27 at 8:24 PM
New long-term share-based incentive programNew long-term share-based incentive program
finance.yahoo.com - April 22 at 10:02 AM
Idiopathic Inflammatory Myopathy Treatment Market Robust Expansion by Top Key Manufactures | Overview by Size, Share, Trends, Segments to 2026Idiopathic Inflammatory Myopathy Treatment Market Robust Expansion by Top Key Manufactures | Overview by Size, Share, Trends, Segments to 2026
marketwatch.com - April 14 at 7:04 AM
CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body MyositisCytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis
finance.yahoo.com - April 1 at 5:00 PM
Why Orphazymes Stock is Down During Todays SessionWhy Orphazyme's Stock is Down During Today's Session
finance.yahoo.com - March 29 at 7:09 PM
Why Is Orphazyme (ORPH) Stock Trading Lower On Monday?Why Is Orphazyme (ORPH) Stock Trading Lower On Monday?
finance.yahoo.com - March 29 at 7:09 PM
Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)
finance.yahoo.com - March 29 at 4:07 AM
Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share UnitsCapital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
markets.businessinsider.com - March 27 at 12:02 PM
Resolutions passed at the Annual General MeetingResolutions passed at the Annual General Meeting
markets.businessinsider.com - March 25 at 5:52 PM
Correction: Notice to convene Annual General MeetingCorrection: Notice to convene Annual General Meeting
finance.yahoo.com - March 3 at 5:29 PM
Notice to convene Annual General MeetingNotice to convene Annual General Meeting
finance.yahoo.com - March 3 at 12:29 PM
Orphazyme reports business highlights and financial results in Annual Report 2020Orphazyme reports business highlights and financial results in Annual Report 2020
finance.yahoo.com - March 2 at 6:25 AM
ORPHAZYME A/S: Orphazyme appoints Christophe Bourdon as Chief Executive OfficerORPHAZYME A/S: Orphazyme appoints Christophe Bourdon as Chief Executive Officer
bloomberg.com - March 1 at 7:40 AM
Orphazyme appoints Christophe Bourdon as Chief Executive OfficerOrphazyme appoints Christophe Bourdon as Chief Executive Officer
finance.yahoo.com - March 1 at 7:40 AM
ORPHAZYME A/S: Orphazyme announces participation in upcoming virtual investor conferencesORPHAZYME A/S: Orphazyme announces participation in upcoming virtual investor conferences
bloomberg.com - February 27 at 8:17 AM
Orphazyme announces participation in upcoming virtual investor conferencesOrphazyme announces participation in upcoming virtual investor conferences
finance.yahoo.com - February 26 at 5:15 PM
Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new sharesCapital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares
finance.yahoo.com - February 25 at 8:37 PM
Orphazyme announces presentation of 2020 Annual ReportOrphazyme announces presentation of 2020 Annual Report
marketwatch.com - February 23 at 12:24 PM
ORPHAZYME A/S DK 1 (1TB.BE)ORPHAZYME A/S DK 1 (1TB.BE)
au.finance.yahoo.com - February 10 at 5:39 PM
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilitiesReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
finance.yahoo.com - February 1 at 2:38 PM
Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching SharesCapital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
markets.businessinsider.com - February 1 at 2:18 PM
(1O3AB.NX)(1O3AB.NX)
ca.finance.yahoo.com - January 22 at 7:04 PM
ORPHAZYME A/S: Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access EventORPHAZYME A/S: Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
bloomberg.com - January 6 at 1:45 AM
Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access EventOrphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
finance.yahoo.com - January 4 at 12:36 PM
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type CCytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C
finance.yahoo.com - December 31 at 2:50 PM
Orphazyme provides regulatory update on arimoclomol for NPCOrphazyme provides regulatory update on arimoclomol for NPC
finance.yahoo.com - December 27 at 5:53 PM
Orphazyme A/S (1TB.F)Orphazyme A/S (1TB.F)
au.finance.yahoo.com - December 26 at 12:50 AM
Orphazyme A/S (1TB.F)Orphazyme A/S (1TB.F)
au.finance.yahoo.com - December 26 at 12:50 AM
News for Orphazyme A-S Bearer and-or registered ShsNews for Orphazyme A-S Bearer and-or registered Shs
markets.businessinsider.com - December 24 at 8:35 AM
This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.